Recursion Pharmaceuticals RXRX Q1 2026 Earnings Narrower Loss Surprises Market but Stock Dips on PreRevenue Status FiscalNote Q1 2026 Earnings EPS Surprise Beats Estimates Despite Stock Decline SLM Q1 2026 Earnings EPS Surges Past Estimates Stock Gains Rocket Pharmaceuticals Inc RCKT Q1 2026 Earnings Clinical Progress Overshadowed by Slight EPS Miss and Capital Concerns PEBK Q4 2025 Earnings EPS of 121 Reported Stock Edges Lower FOXA Q1 2026 Earnings EPS Beat by Over 33 Drives Positive Market Reaction